Avalon Globocare Corp. · NASDAQ:ALBT
Avalon Globocare — Investor Presentation (June 2023)
15 slides from Avalon Globocare's investor presentation, Jun 16, 2023
Slide 1: June 2023 Corporate Presentation
Nasdaq: ALBT www.avalon - globocare.com June 2023 Corporate Presentation
Slide 2: Forward-Looking Statements
Certain statements contained in this presentation may constitute “forward - looking statements”, which provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact . Actual results may differ mate
Slide 3: Corporate Overview and Highlights
3 Nasdaq: ALBT Mission: Avalon GloboCare Corp. (Nasdaq: ALBT) is a commercial stage company dedicated to developing and delivering innovative, transformative, precision diagnostics and clinical laboratory services. History: Founded in 2016; successfully uplisted to Nasdaq in December 2018; Acquired
Slide 4: Senior Management Team
4 Nasdaq: ALBT David Jin, M.D., Ph.D. CEO, President, Co - founder, BoD U.S. Licensed Physician; Former Medical Resident, Fellow and Faculty Member at Weill Cornell Medicine and New York - Presbyterian Hospital; Senior Clinician - Scientist at Ansary Stem Cell Institute; Former CMO of BioTime Inc. a
Slide 5: Board of Directors
5 Nasdaq: ALBT Board of Directors Steven Sanders, J.D. Director, Co - Chair of Compensation Committee Founder of Ortoli Rosenstadt Law Firm, NYC William Stilley Director, Chairman of Audit Committee CEO of Purnovate , an Adial company (NASDAQ: ADIL) Lourdes Felix Director, Chief Executive Officer, C
Slide 6: Overview of Laboratory Services MSO
6 Nasdaq: ALBT • Well - established and sustainable reference lab testing infrastructure and client networks; over 600,000 tests completed since inception • Highly profitable “out - of - network” services (about 90%) combined with high volume “in - network” option for customers • Strong opportunity
Slide 7: Laboratory Services MSO Acquisition
7 Nasdaq: ALBT Lab o ratory Services MSO Acquistion Genetic Testing Lab Services • Accelerate precision diagnostics related to better, safer future development of genetic based testing • Large - scale lab testing related to immune system functionality, pharmacogenomics, toxicology monitoring and imm
Slide 8: Laboratory Services MSO: State-of-the-Art Testing Facility in Costa Mesa, CA
8 Nasdaq: ALBT Laboratory Services MSO: State - of - the - Art Testing Facility in Costa Mesa, CA
Slide 9: Competitive Landscape
9 Nasdaq: ALBT Competitive Landscape • The clinical laboratory services market in the United States is anticipated to grow at a CAGR of 4.2% during the forecast period of 2023 - 2030, reaching a valuation of US$ 125.6 Billion by 2030 • The competitive landscape of the US clinical laboratory services
Slide 10: Laboratory Services 2022 Financial Highlights
10 Nasdaq: ALBT Lab o ratory Services 2022 Financial Highlights • Revenue $ 14 . 7 million • Gross profit $ 8 . 1 million • Total operating expense $ 2 . 4 million • Net income $ 6 . 3 million
Slide 11: Laboratory Services MSO - Market Position and Key Differentiators
11 Nasdaq: ALBT Laboratory Services MSO - Market Position and Key Differentiators • Unparalleled customer service • Broad test menu from general bloodwork to anatomic pathology, urine toxicology, and more • Fast turn - around time • Highly profitable “ Out - of - Network” services combined with high
Slide 12: Volatile Organic Compound (VOC) based Nanosensors Technology
12 Nasdaq: ALBT Volatile Organic Compound (VOC) based Nanosensors Technology Multiple VOCs “Breathprint” POCT • AI - based computational algorithm • “Breathprint” VOC bomarkers and database • Single - use sensor cartridge for different disease detection • Point - of - care portable device Single VOC
Slide 13: Summary: Intellectual Property, Laboratory Services and Nanosensor Technology
13 Nasdaq: ALBT Summary Intellectual Property Laboratory Services and Precision Dx Nanosensor Technology Avalon has Embarked on Lab Rollup Strategy Jointly Filed Patents (including USPTO, PCT) • Toxicology testing and monitoring • Development and commercialization of testing kits and systems • Oppor
Slide 14: Capitalization
14 Nasdaq: ALBT Capitalization Common Shares Outstanding Stock Price Insider Ownership Market Cap Base of Operation Freehold, NJ $1.87 19.1 M 56.8% 10.2 M 1 1 1 .Based on Nasdaq closing price on June 2, 2023
Slide 15: Contact
Nasdaq: ALBT www.avalon - globocare.com Contact: Corporate Address: Avalon Executive Center 4400 Route 9 South, Suite 3100 Freehold, New Jersey 07728, USA Phone: +1 – 732 - 780 - 4400 Fax: +1 – 732 - 780 - 5600 Website: www.avalon - globocare.com IR Email: albt@crescendo - ir.com Thank You